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Adnan Qureshi 3
1Department of Neurology and Radiology, University of Texas Rio Grande Valley, Harlingen, TX, United States, 2Department
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Background: Previous research has focused on the association between hemorrhagic
transformation (HT) incidence and pre-procedural variables (i.e., baseline variables) rather
than the association between HT incidence and endovascular treatment (EVT) procedural
variables (e.g., stent retriever passes).
Objective: To assess the association, if any, that exists between the number of
stent retriever passes per procedure and the incidence of HT for patients undergoing
mechanical thrombectomy.
Methods: An endovascular database from a comprehensive stroke center was used to
collect data on EVT patients treated with Trevo, Solitaire, or Penumbra stent retrievers
from the years 2012 to 2017. Statistical analyses were conducted on the stent
retriever passes, demographics, morbidities, medication usage, and outcomes and their
association with HT.
Results: Of the 329 total patients, 46 (14%) had HT. The HT group had an average
[SD] of 1.65 [0.67] and range of [1–3] passes per procedure while the non-HT group
had an average [SD] of 1.63 [0.86] and range of [1–5] passes per procedure. Admission
NIHSS score (p = 0.0003) and the incidence of diabetes mellitus (DM) (p = 0.05) were
significantly higher in the HT group. Subdividing HT into symptomatic and asymptomatic
ICH groups failed to display significant differences in the distribution of the stent retriever
passes (p = 0.969). The number of passes failed to show any association with HT
(p = 0.804) while admission NIHSS score was found to have an OR of 1.07 (95%CI:
1.029–1.121, p = 0.001) with HT incidence.
Conclusion: No significant association was found between HT incidence and the stent
retriever passes. Further multicenter studies are warranted to corroborate our results.
Keywords: thrombectomy, hemorrhagic transformation (HT), stent retriever, endovascular, intracranial
hemorrhage
Hassan et al. Stent-Retriever Passes and Hemorrhagic Transformation
INTRODUCTION
Hemorrhagic transformation (HT) presents as a prolific
complication to any patient undergoing reperfusion therapies
such as IV thrombolysis and/or endovascular treatment (EVT).
HT, particularly the parenchymal hematoma version 2(PH-2),
significantly increases the risk of subsequent neurological
deterioration and mortality (1). While several HT subtypes have
been documented to be more clinically relevant than others (i.e.,
HT-1, HT-2, etc.), our study was primarily a safety outcomes
analysis between the overall incidence of HT and the number of
stent retriever passes.
Previous research has identified several pre-procedural risk
factors of HT for acute ischemic stroke patients including pre-
existing morbidities such as “atrial fibrillation (AF), diabetes
mellitus (DM), and congestive heart failure (CHF)” (2–4),
radiographic biomarkers such as “relative CBV values, relative
CBF values, and collateral flow” (5), laboratory values such as
“platelet count, glucose levels, and levels of total cholesterol”
(2) and clinical variables such as admission NIHSS score (6).
Several studies have utilized such pre-procedural variables to
create strong predictive models for the incidence of HT. For
example, Kalinin et al. created the Hemorrhagic Transformation
Index (HTI) to predict HT incidence within 14 days for acute
ischemic stroke patients using the Alberta Stroke Program Early
CT (ASPECTS) score, NIHSS score, hyperdense MCA sign, and
incidence of Atrial Fibrillation upon admission (6).
Despite recently proliferating research, the impact of
procedural factors such as stent retriever passes on HT has not
been well-established in the era of stent-retrievers. Current stent
retriever manufacturers recommend a maximum of 2 passes
per device and not more than 3 passes per vessel as per the IFU
(Medtronic, Irvine, CA).
Our aim with this paper is to elucidate a potential association,
if any, between the number of passes with a stent retriever and
the incidence of HT. This study is to be regarded primarily
as a safety outcomes analysis, although clinical outcomes are
discussed extensively as well.
METHODOLOGY
All acute ischemic stroke patients who underwent EVT with a
stent retriever were selected from a prospectively maintained
endovascular database of a comprehensive stroke center from
2012 to 2017. A modified “Solumbr” approach was utilized
in which a guide catheter, a distal access catheter and a
microcatheter were used to cross the lesion. A stent retriever
was subsequently deployed for 5–7min and pulled back slightly
under aspiration to cork it into the distal access catheter, and
then both were removed together slowly while under constant
aspiration via a pump. Heparin is not administered in any
of our stroke cases; however, 2,000 units/bag are connected
to the flush lines. GP2b/3a inhibitors are not routinely used.
EVT is typically terminated after 60min of intervention time
(7, 8). Baseline clinical characteristics, endovascular procedural
variables, safety outcome rates, and patient outcomes were
gathered from the selected patients. Baseline characteristics
included patient demographic data, pre-existing morbidities,
medication usage, pre-procedural mTICI score, admission
NIHSS score, occlusion location, and admissionmodified Rankin
Scale (mRS) score (Table 1). Endovascular procedural variables
included the number of passes per operation with a stent
retriever, time from stroke onset to arrival at hospital, time from
emergency department (ED) arrival to time of recanalization, and
time from groin puncture to time of successful recanalization
(defined as mTICI 2b-3), stent-retriever sizing, and catheter type.
Safety outcome data included incidence of HT, mass effect, and
intracranial hemorrhage (ICH). HT was defined as any ICH in
the territory of the initial ischemic event during hospitalization
and confirmed by multiple non-contrast head CT scans or MRIs
of the brain according to radiology. HT incidence was further
subdivided into asymptomatic ICH and symptomatic ICH.
Symptomatic ICH was defined as a neurological deterioration of
4+ points in the NIHSS scale score within 24 h post-procedure.
Patients who received mechanical thrombectomy using Trevo,
Solitaire, or Penumbra stent retrievers were dichotomized
according to the incidence of HT. Patient outcomes were assessed
by analyzing post-procedure NIHSS and mRS scores as well as
mortality rate. NIHSS scores were collected upon admission,
24 h post-procedure, and time of discharge. The mRS scores
were specifically used to assess functional independence and were
collected upon admission, time of discharge, as well as at 90
day follow ups. Patients with an mRS score between 0 and 2
were deemed functionally independent at the time of collection.
The study and protocol were approved by the local Metro West
Institutional Review Board.
STATISTICAL ANALYSIS
Patient data were dichotomized according to the incidence of
HT and analyzed via univariate and multivariate analyses. To
assess statistical significance between the collected variables and
the incidence of HT, a 2-sample t-test was performed on the
continuous variables while Fisher’s Exact test was performed
on the categorical variables. Statistically significant data (i.e.,
p < 0.1) were analyzed further. A multivariate logistical analysis
was conducted in which all statistically significant variables were
incorporated together in addition to the number of passes per
procedure to develop odds ratios for the incidence of HT. All
statistical analyses were conducted using IBM SPSS Statistics.
RESULTS
A total of 329 patients underwent EVT with a stent retriever
between the years 2012 and 2017. Forty-six (14%) patients
developed HT (HT+) while the remaining 283 (86%) did not
(HT–). The average age for all patients was 71 ± 12.9 and the
mean admission NIHSS score for all patients was 16.7 ± 7.9.
Additionally, the mean time of onset to time of arrival at the
hospital was 4.08 ± 4.17 h while mean time from ED arrival to
recanalization was 57.95± 27.44min, and mean time from groin
puncture to recanalization was 40.95± 26.33min. Recanalization
was achieved in 297 (90%) of all patients while good clinical
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TABLE 1 | Results from the univariate statistical analyses performed on baseline
variables and endovascular procedural variables between HT(+) and HT(–)
patients.
Baseline variables HT(+) (46) HT(–) (283) p-value
Age (mean) [SD] 71.9 [11.17] 70.7 [13.2] 0.527
Ethnicity
African (%) 0 (0%) 1 (0.35%)
Hispanic (%) 35 (76.1%) 206 (72.8%)
White (%) 11 (23.9%) 74 (26.1%)
Other (%) 0 (0%) 2 (0.71%) 0.889
Sex
Male (%) 23 (50.0%) 149 (52.7%)
Female (%) 23 (50.0%) 134 (47.3%) 0.7529
NIHSS score upon admission
(median) [range]
20.59 [6.25] 16.05 [7.97] 0.00027
Morbidities
Hypertension (%) 41 (89.1%) 250 (88.3%) 0.99
CHF (%) 2 (4.3%) 32 (11.3%) 0.195
CAD (%) 13 (28.3%) 88 (31.1%) 0.8633
Hyperlipidemia (%) 24 (52.2%) 163 (57.6%) 0.5233
Currently smoking (%) 2 (4.3%) 29 (10.2%) 0.2804
Diabetes mellitus (%) 27 (58.7%) 121 (42.8%) 0.0548
History of stroke/TIA (%) 10 (21.7%) 63 (22.3%) 0.99
Pre-treatment IV tPA (%) 22 (47.8%) 113 (39.8%) 0.334
Pre-procedure mTICI score
0 (%) 41 (89.10%) 239 (83.0%)
1 (%) 2 (4.35%) 26 (9.19%)
2a (%) 3 (6.52%) 18 (6.0%) 0.551
Occlusion location
MCA 29 (63.04%) 192 (67.77%)
Carotid 13 (30.43%) 66 (23.30%)
M2 2 (4.35%) 9 (3.18%)
PCA, VA, ACA 2 (4.35%) 16 (5.65%) 0.844
Tandem occlusion 8 (17.4%) 79 (27.9%) 0.133
Procedural variables
Number of passes per
procedure
1 21 (45.7%) 156 (55.1%)
2 20 (43.5%) 84 (29.7%)
3 5 (10.9%) 31 (11.0%)
4 0 (0%) 9 (3.2%)
5 0 (0%) 2 (0.71%) 0.201
Time from:
Onset to arrival (hours) [SD] 4.02 [4.21] 4.39 [4.00] 0.626
ED arrival to recanalization
(minutes) [SD]
53.50 [15.37] 58.68 [29.4] 0.245
Groin puncture to recanalization
(minutes) [SD]
37.13 [15.47] 41.57 [28.1] 0.297
Stent-retriever sizing*
3x, 4x (%) 20 (50%) 123 (48.8%)
6x (%) 20 (50%) 129 (51.2%) 0.889
Catheter type
Guide catheter (%) 46 (100%) 275 (97.2%)
Balloon catheter (%) 0 (0%) 8 (3.2%) 0.606
* Size 5x not included in analysis.
outcome (mRS 0–2 after 90 days) was achieved in 46% of all
patients and the rate of mortality at 90 days was 28%.
Table 1 displays the results from the univariate statistical tests
performed on the baseline variables and endovascular procedural
variables between HT(+) and HT(–) patient groups. The HT(+)
patients had a range of 1–3 passes per procedure while the
HT(–) patients had a range of 1–5 passes per procedure. While
the number of passes with a stent retriever for HT(+) patients
held a median of 2 and a mean of 1.652 ± 0.67, the median
for HT(–) patients held a median of 1 and a mean of 1.63 ±
0.86. Subsequent statistical analyses, namely the Fisher exact
test (p = 0.201) and multivariate logistical analysis (OR: 1.023,
p = 0.903, 95% CI: 0.903–1.023), displayed these differences
to be statistically insignificant. Admission NIHSS score (p =
0.00027) and incidence of diabetes mellitus (DM) (p = 0.055)
were both found to have statistically significant association with
the rate of HT. The HT(+) group had an Intravenous tissue
Plasminogen Activator (IV tPA) usage rate of 47.8% while the
HT(–) group had an IV tPA rate of 39.8% (p = 0.334). None of
the temporal procedural variables, namely the time from onset to
arrival at hospital (p = 0.623), time from arrival at ED to time
of recanalization (p = 0.245), or time from groin puncture to
time of recanalization (p= 0.297), were found to have significant
association with HT.
Table 2 displays the results from comparing the distribution
of the number of passes between asymptomatic ICH and
symptomatic ICH subdivisions of the HT (+) group. Our study
found a remarkably similar distribution of the number of passes
between both groups (p= 0.969).
Table 3 delineates the results from the univariate statistical
tests performed on endovascular safety outcome rates and patient
outcomes between HT(+) and HT(–) patient groups. Significant
safety outcome data included higher rates of symptomatic ICH (p
< 0.0001), asymptomatic ICH (p < 0.0001), as well as mass effect
(p < 0.0001) for the HT(+) group. Significant patient outcome
data included higher NIHSS 24-h score (p <0.0001), NIHSS
discharge score (p= 0.00012), mRS discharge score (p= 0.0005),
mRS 90-day score (p = 0.0278), and incidence of death up to 90
days (p= 0.0044) for theHT(+) group. The significant admission
NIHSS score, 24-h NIHSS score, and discharge NIHSS score data
obtained warranted additional statistical testing to investigate
the amount of change in NIHSS score between both groups
[i.e., HT(+) vs. HT(–)], namely the intergroup difference in the
change between NIHSS score at 24-h and admission NIHSS (p=
0.0521).We also looked at the intergroup difference in the change
between admission and discharge NIHSS score (p= 0.0203). The
TABLE 2 | Results from comparing the distribution of the number of passes
between symptomatic ICH and asymptomatic ICH groups.
Number of passes Symptomatic
ICH (11)
Asymptomatic
ICH (35)
p-value
1 5 (45.5%) 16 (45.7%)
2 5 (45.5%) 15 (42.9%)
3 1 (9.1%) 4 (11.4%) 0.969
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HT(–) group had a 3.44 ± 8.8 decrease from admission NIHSS
score to 24-h score and a 3.90 ± 13.1 decrease from admission
to discharge NIHSS score while the HT(+) group had a decrease
of 0.63 ± 8.22 points from admission to 24-h NIHSS score but
an increase of 1.40 ± 15.42 points from admission to discharge
NIHSS score. The large SD values are largely attributable to the
presence of negative NIHSS difference values.
Subsequently, a multivariate logistic regression was performed
using the statistically significant variables as predictor variables
and the incidence of HT as the dependent variable (Table 4).
The only significant predictor variable for HT obtained from
multivariate logistic regression however was NIHSS admission
score, which held an OR of 1.074 (p = 0.001; 95% CI: 1.029,
1.121). The number of passes with a stent retriever variable
(p = 0.804) showed no statistically significant impact upon the
multivariate logistical regression of the incidence of HT.
DISCUSSION
This study has shown that the number of passes with a stent
retriever is not significantly associated with the incidence of HT.
While the difference in the distribution of the number of passes
TABLE 3 | Results from the univariate statistical tests performed on safety
outcome rates and patient outcomes between HT(+) and HT(–) patient groups.
Clinical outcomes HT(+) (46) HT(–) (283) p-value
Recanalization (%) 41 (89.1%) 261 (92.2%) 0.478
mRS (0–2) upon discharge (%) 3 (6.5%) 84 (29.7%) 0.0005
mRS (0–2) upon 90 days (%) 10 (21.7%) 89 (31.4%) 0.0278
Death (%) 18 (39.1%) 57 (20.1%) 0.0044
NIHSS upon 24 h (median)
[range]
21 [1–34] 12 [0–32] <0.0001
NIHSS upon discharge (median)
[range]
18 [1–42] 8 [0–42] 0.0002
NIHSS DIFFERENCES
NIHSS upon 24 h—NIHSS upon
admission (mean) [SD]
−0.63 [8.22] −3.44 [8.8] 0.0521
NIHSS upon discharge—NIHSS
upon admission (mean) [SD]
+1.40 [15.32] −3.90 [13.1] 0.0203
SAFETY OUTCOMES
Asymptomatic ICH (%) 35 (76.1%) 11 (3.9%) <0.0001
Symptomatic ICH (%) 11 (23.9%) 8 (2.3%) <0.0001
Mass effect (%) 15 (32.6%) 18 (6.4%) <0.0001
TABLE 4 | Results from multivariate regression analyses using NIHSS score upon
admission and incidence of DM to predict the incidence of HT.
Baseline variables
with univariate p <
0.1
OR p-value Lower 95% CI
boundary
Upper 95% CI
boundary
NIHSS 1.074 0.001 1.029 1.121
*DM 1.85* 0.069* 0.954* 3.57*
*Deemed insignificant because of p > 0.05 and 95% CI being both below and above 1.
per procedure between HT(+) and HT(–) groups was found to
be insignificant (p = 0.201), a wider range of passes [1–5] was
observed in the HT(–) group than that of the HT(+) group [1–3].
While admission NIHSS scores have historically held strong
association with post-procedure functional independence rates,
our study found that admission NIHSS score was likewise
significantly associated with the incidence of HT within both
univariate and multivariate analyses. Prevalence of DM was an
additional baseline variable associated with the incidence of HT
in our univariate analysis (p = 0.055). Jiang et al. found that the
risk of symptomatic ICH in diabetic patients had an OR ≥ 7
in both univariate and multivariate models, hypothesizing that
the substantial risk was in part due to the increased vascular
aging typical of diabetic patients (9). Hyperglycemia, although
not directly measured in our study, has also been associated with
increased rates of reperfusion injury and lower rates of both
recanalization (mTICI 2b-3) and functional independence post-
procedure (10). The temporal procedural variables in our study,
namely the time from stroke onset to time of hospital arrival, time
from arrival at ED to time of recanalization, and time of groin
puncture to time of recanalization failed to show any significant
association with HT. Jiang et al. found that increased time
between groin arterial access and recanalization was significantly
associated with higher rates of symptomatic ICH (OR 1.01, 95%
CI: 1.00–1.02) as well as functional outcome OR 2.97, 95% CI
1.00–8.83 (9). However, the average groin to recanalization time
of 114.51± 63.65 (9) min reported by Jiang et al. was significantly
greater than of the average time of 40.95± 26.33min observed in
our study.
The HT(+) patient group had significantly higher NIHSS
scores at 24 h post-procedure (p = 0.0005) and at the time of
discharge (p= 0.0002) compared to theHT(–) group. TheHT(+)
group was also found to have significantly lower proportions
of patients with post-operative functional independence (mRS
0–2) at discharge (p = 0.0005) as well as at 90 days (p =
0.0278) compared to the HT(–) group. Arimura et al. likewise
found that postoperative ICH incidence was highly associated
with decreased rates of functional independence upon 90 days
(p= 0.004) (11).
Subdividing HT into asymptomatic ICH and symptomatic
ICH groups did not show any significant differences in the
distribution of the number of stent retriever passes (p = 0.969).
As such, our study seems to support the inference that the 4+
increase in NIHSS score indicative of symptomatic ICH was not
significantly attributable to the number of stent retriever passes.
Another significant finding in our study was that the majority
of ICH (70.8%) were asymptomatic. Gill et al. obtained similar
results upon analyzing safety outcome rates of previous stent
retriever trials (i.e., Solitaire, Trevo, and preSet trials), in which he
found that 1–5% of all cases were documented with symptomatic
ICH while 7–30% were documented with asymptomatic ICH
(12). Procedural risk factors exclusive to EVT only such as
mechanical perforation or dissection of the vessel wall, stent-
retriever size, catheter type, improper visualization of artery via
x-ray fluoroscopy, as well as lesions acquired through retrieving
stent-devices have been posed as explanations for this aberrant
increase in ICH frequency (13, 14).
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LIMITATIONS
This study was performed retrospectively and was not
randomized. Although it is established that certain categories
of HT exist (i.e., HT-1, HT-2, etc.) that are not as clinically
salient as others, our study regards HT as a safety outcome
and includes the overall incidence of HT. Furthermore, given
that procedural variables have been found to be highly variable
between institutions (e.g., the significantly different times
between groin puncture and recanalization across institutions
noted above) our findings may not be generalizable to a very
large-scale context. Corroboratory evidence would consist of
multicenter retrospective studies and/or studies with larger
ranges of stent retriever passes per procedure investigating
our claim.
CONCLUSION
This study found the number of passes with a stent
retriever to be insignificantly associated with the incidence
of HT. Admission NIHSS score and to a lesser degree
DM were found to be much more associated with the
incidence of HT. While our study primarily focused
on the number of stent retriever passes, continuing to
delimit and investigate other procedural variables are
imperative steps toward improving safety outcome rates
and patient outcomes.
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